Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.

Antimicrobial agents and chemotherapy, Volume: 66, Issue: 4
April 19, 2022
Gregory S Basarab GS, Sandeep Ghorpade S, Liezl Gibhard L, Rudolf Mueller R, Mathew Njoroge M, Nashied Peton N, Preshendren Govender P, Lisa M Massoudi LM, Gregory Thomas Robertson GT, Anne J Lenaerts AJ, Helena Ingrid Boshoff HI, Douglas Joerss D, Tanya Parish T, Thomas F Durand-Reville TF, Manos Perros M, Vinayak Singh V, Kelly Chibale K

Described here is a series of spiropyrimidinetrione (SPT) compounds with activity against Mycobacterium tuberculosis through inhibition of DNA gyrase. The SPT class operates via a novel mode of inhibition, which involves Mg-independent stabilization of the DNA cleavage complex with DNA gyrase and is thereby not cross-resistant with other DNA gyrase-inhibiting antibacterials, including fluoroquinolones. Compound 22 from the series was profiled broadly and showed cidality as well as intracellular activity against M. tuberculosis in macrophages. Evidence for the DNA gyrase mode of action was supported by inhibition of the target in a DNA supercoiling assay and elicitation of an SOS response seen in a reporter strain of M. tuberculosis. Pharmacokinetic properties of 22 supported evaluation of efficacy in an acute model of M. tuberculosis infection, where modest reduction in CFU numbers was seen. This work offers promise for deriving a novel drug class of tuberculosis agent without preexisting clinical resistance.

Courtesy of the U.S. National Library of Medicine